From the mechanistic point of view, one of the main perspectives of this study is to test if the quinazoline-based derivatives, for instance, 12, is DNA -substrate competitive. This will be done through enzymatic DNA-substrate competitive assays. The results will be reported in due course. In all, the results of this work contribute to the further investigation and development of DNMTi as part of multiple epigenetic target therapies.